Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas.
Details
Download: 37886714_BIB_74F958EEF645.pdf (666.29 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_74F958EEF645
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas.
Journal
Therapeutic advances in vaccines and immunotherapy
ISSN
2515-1355 (Print)
ISSN-L
2515-1355
Publication state
Published
Issued date
2023
Peer-reviewed
Oui
Volume
11
Pages
25151355231206163
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Publication Status: epublish
Abstract
Diffusely infiltrating gliomas - including glioblastoma (GBM), isocitrate dehydrogenase (IDH) mutant gliomas, and histone 3 (H3) altered gliomas - are primary brain tumors with an invariably fatal outcome. Despite advances in the understanding of their biology, standard, targeted and immune checkpoint inhibitor immunotherapies have proven ineffective in arresting their inexorable progression and associated morbidity and mortality. Recognizing the unique aspects of the immunogenicity of cancer cells, the last decade has seen the development and evaluation of vaccine-based therapies for the treatment of solid tumors, including gliomas. Here we review the current vaccine strategies for the treatment of GBM, IDH-mutant gliomas and diffuse midline glioma H3 K27M-altered. We discuss potential benefits and challenges of vaccine therapies in these specific patient populations.
Keywords
IDH-mutant Glioma, diffuse midline glioma, glioblastoma, glioma, immunotherapy, vaccine
Pubmed
Open Access
Yes
Create date
30/10/2023 12:26
Last modification date
09/08/2024 16:01